[ad_1]
A new drug containing favipiravir, manufactured by the pharmaceutical company Egis, has been approved by the National Institute of Pharmacy and Food Health (OGYÉI) for the treatment of coronavirus, the institute informed MTI this Saturday.
According to the announcement The drug is expected to be used in mid-January for the treatment of coronavirus patients, the product is managed by the state health reserve and delivered to health care providers.
The Egis pharmaceutical company began development of drugs containing favipiravir in April, as a result of which OGYÉI approved the drug for use in Hungary on Friday. OGYÉI conducted the evaluation of Egis favipiravir-containing products in an accelerated procedure. After reviewing the authorization file, the Authority decided on the national authorization of the product. they explained.
The institute emphasized that OGYÉI considers it a priority to carry out its tasks related to the treatment of coronavirus and the prevention of Covid infection.In recent months, drug-related developments in coronavirus patients have started and are continuing at an unprecedented rate, both in Hungary and in other countries.they wrote.
OGYÉI also assisted in the Egis medicine development process with multiple consultations during the licensing process, the aim of which was to enable the right quality medicine to be marketed and delivered to Hungarian patients as soon as possible. OGYÉI provides this support to all Hungarian manufacturers, the institute said.
At the same time, they emphasized: OGYÉI also does not allow strict quality requirements in the expedited procedure. In terms of drug safety, the Hungarian practice is world class and OGYÉI’s main goal is to bring only drugs of the right quality to market.
It is of utmost importance for the Institute to support developments related to the coronavirus and, like the European Medicines Agency, to completely waive scientific advice fees for developers of medicines or vaccines to prevent or treat Covid infection. 19 from the first wave of the epidemic, and continuing also prioritizes applications related to the treatment of coronavirus in order to ensure the highest level of care for the Hungarian population.
Favipiravir is the second drug used in Covid therapy after remdesivir and has been approved by OGYÉI for home use.
[ad_2]
